Insulin Glargine-aglr Injection
Eli Lilly and Co.
Open FDA's page for this record- Discontinued date
- 09/01/2026
- Update type
- New
- Initial posting date
- 09/01/2026
- Package NDC
- 0002-8980-05
- Generic name
- Insulin Glargine-aglr Injection
- Contact info
- 800-545-5979
- Update date
- 09/01/2026
- Dosage form
- Injection
- Presentation
- Rezvoglar, Injection, 100 [iU]/1 mL (NDC 0002-8980-05)
- Company name
- Eli Lilly and Co.
- Status
- To Be Discontinued
- Related info
A business decision was made to discontinue manufacture of the drug. Distribution projected to end June 2027. If patients or prescribers have any questions, the Lilly Answers Center (1-800-545-5979) is available Monday through Friday from 9am to 8pm for assistance.
- Therapeutic category
- Endocrinology/Metabolism
- Harmonized identifiers (openFDA)
- Application number
- BLA761215
- Brand name
- REZVOGLAR KWIKPEN
- Generic name
- INSULIN GLARGINE-AGLR
- Manufacturer name
- Eli Lilly and Company
- Product NDC
- 0002-8980
- Product type
- HUMAN PRESCRIPTION DRUG
- Route
- SUBCUTANEOUS
- Substance name
- INSULIN GLARGINE
- RxCUI
- 2589008, 2589014
- SPL ID
- a9e95b4c-e280-4bef-a3dd-4907bfad6b4d
- SPL set ID
- f6af8706-2058-4fe1-99c8-43684c20bfa2
- Package NDC
- 0002-8980-01, 0002-8980-05
- Nui
- M0011417, N0000175453
- Pharm class cs
- Insulin [CS]
- Pharm class epc
- Insulin Analog [EPC]
- UNII
- 2ZM8CX04RZ
